Thu 5/24/2018 09:28 ET
S&P 5002733.298.750.32%BANKS28.160.000.01%OIL62.241.051.69%BITCOIN7494.1711.240.15%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Penny Stocks (CHINESEINVESTORSCOM - CIIX)   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add CIIX
From: NetworkNewsWire (Rep: 0)Date: 03/07/2017 16:26
Forum: Penny Stocks - Msg #347 - List CIIX msgs Thread #673911936 (Rec: 0)
SeeThruEquity Issues Update on (CIIX), Increases Price Target to $3.75

Less than two weeks after making a presentation at the SeeThruEquity Conference in Miami Beach, SeeThruEquity increased its price target for (OTCQB: CIIX) to $3.75. The previous price target for CIIX, issued in October 2016, was $2.05. SeeThruEquity delivers unbiased and unpaid for equity research for publicly traded companies with market capitalizations of less than $1 billion. The increased target price reflects the added potential from legal cannabis initiatives taken by Though in the early stages of penetrating the legal cannabis market, has demonstrated prior success with its profitable investment in Medicine Man Technologies, generating $2.3 million in proceeds from stock sales of Medicine Man in 2016.

Traditionally, has delivered a broad range of products, services, and information for the Chinese speaking population, estimated at 1.2 billion people worldwide. The company provides real-time market commentary, analysis, and educational services in the Chinese language, and it offers several types of subscription-based services. Founded in 1999, the company is headquartered in Los Angeles with offices in New York City and Shanghai, China. also offers consultation services to private companies seeking to go public, as well as advertising and public relations services.

With a focus on value-added opportunities, the company has recently expanded into retail and online sales of cannabidiol (CBD) products. CBD is considered to have a broad range of potential medical applications, including the treatment of epilepsy. With multiple anecdotal claims of CDB efficacy in treating epilepsy, Great Britain-based GW Pharmaceuticals is seeking FDA approval to market a liquid formulation of pure plant-derived CBD. Clinical reports show CBD is devoid of the euphoric side effects associated with THC. markets CBD products to the Chinese people through its website,

Although early in market penetration, is among the very first to capitalize on selling CBD products to 1.2 billion Chinese people. The company has previously exhibited the ability to identify and execute upon opportunity. Given its track record, it should come as no surprise if CIIX succeeds in this new venue and, subsequently, achieves SeeThruEquity’s price target.

For more information, visit the company’s website at

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser NetworkNewsWire: Reward | Watch | IgnoreCIIX: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add CIIX | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999-, Inc.